Protein Engineering Market Report by Product & Services, Protein Type, Technology, End User, and Region 2024-2032
세계의 단백질 엔지니어링 시장 규모는 2023년 33억 달러에 달했습니다. 향후 IMARC 그룹은 시장이 2032년까지 78억 달러에 이르며 2024년과 2032년 사이에 9.9%의 성장률(CAGR)을 보일 것으로 예측했습니다.
단백질 엔지니어링은 단백질의 염기서열을 개발하거나 변경하여 원하는 결과를 얻는 과정을 말합니다. 새로운 단백질의 합성과 기존의 구조와 서열의 변경을 포함하고 새로운 기능 강화를 위해 아미노산 서열을 변경하는 재조합 데옥시리보 핵산(DNA) 기술을 이용합니다. 이 기술은 산업적으로 사용되는 효소와 단백질의 대량 생산에 널리 사용됩니다. 최근 연구자들은 의료, 연구, 산업, 건강, 생명공학 분야에 맞는 다양한 단백질의 설계에 성공하여 전 세계적으로 수요가 증가하고 있습니다.
단백질 엔지니어링 시장 동향 :
합성 생물학에 대한 투자 증가와 단백질 기반 의약품 개발에 대한 관심 증가는 시장 개척의 주요 촉진요인이되었습니다. 또한, 단백질 의약품의 임상 결과가 양호하기 때문에 비단백질 의약품에서 단백질 치료제로의 이동이 현저합니다. 이것은 단백질 결핍 질환의 만연과 함께 단백질 공학 수요를 증가시키고 있습니다. 또한, 단백질 공학 분야의 R&D(R&D) 활동에 대한 자금 제공 증가 등 각국 정부의 몇 가지 유리한 노력이 시장 성장을 가속하고 있습니다. 이에 더해 재조합 단클론항체(mAbs)의 등장과 암이나 자가면역 질환 등 다양한 질환의 치료에 있어서의 단클론항체의 사용량 증가가 제품의 채용률을 가속화하고 있습니다. 또한 농약업계에서는 작물의 수확량을 늘리거나 바이오연료의 생산을 촉진하기 위해 기능을 강화한 효소를 생성하는 단백질공학의 응용연구가 진행되고 있어 시장성장 촉매와 되어 있습니다. 개인화된 의약품에 대한 수요 증가, 바이오시밀러 및 생물학적 제제에 대한 요구 증가, 건강 관리 인프라 개선, 기술 발전, 제품 혁신 등 기타 요인들도 시장에 밝은 전망을 제공합니다.
이 보고서에서 다루는 주요 질문
- 2023년 세계 단백질 엔지니어링 시장 규모는?
- 2024-2032년 세계 단백질 엔지니어링 시장의 예상 성장률은?
- 세계의 단백질 엔지니어링 시장을 견인하는 주요 요인은?
- 세계의 단백질 엔지니어링 시장에 대한 COVID-19의 영향은?
- 세계의 단백질 엔지니어링 시장의 제품 및 서비스별 내역은?
- 세계의 단백질 엔지니어링 시장의 단백질 유형별 고장은?
- 세계의 단백질 엔지니어링 시장의 최종 사용자별 내역은?
- 세계의 단백질 엔지니어링 시장의 주요 지역은?
- 세계의 단백질 엔지니어링 시장의 주요 기업/기업은?
목차
제1장 서문
제2장 조사 범위와 조사 방법
- 조사의 목적
- 이해관계자
- 데이터 소스
- 시장 추정
- 조사 방법
제3장 주요 요약
제4장 소개
제5장 세계의 단백질 엔지니어링 시장
- 시장 개요
- 시장 실적
- COVID-19의 영향
- 시장 예측
제6장 시장 분석 : 제품?서비스별
제7장 시장 분석 : 단백질 유형별
- 인슐린
- 단클론항체
- 응고 인자
- 백신
- 성장인자
- 기타
제8장 시장 분석 : 기술별
제9장 시장 내역: 최종 사용자별
- 제약 및 바이오테크놀러지 기업
- 학술연구기관
- 계약 연구 기관
제10장 시장 내역: 지역별
- 북미
- 아시아태평양
- 유럽
- 독일
- 프랑스
- 영국
- 이탈리아
- 스페인
- 러시아
- 기타
- 라틴아메리카
- 중동 및 아프리카
제11장 SWOT 분석
제12장 밸류체인 분석
제13장 Porter's Five Forces 분석
- 개요
- 구매자의 협상력
- 공급기업의 협상력
- 경쟁도
- 신규 참가업체의 위협
- 대체품의 위협
제14장 가격 분석
제15장 경쟁 구도
- 시장 구조
- 주요 기업
- 주요 기업 프로파일
- Abzena Ltd.
- Agilent Technologies Inc.
- Amgen Inc.
- Bio-Rad Laboratories Inc.
- Bruker Corporation
- Codexis Inc.
- Danaher Corporation
- Eli Lilly and Company
- General Electric Company
- Merck KGaA
- Novo Nordisk A/S
- PerkinElmer Inc.
- Thermo Fisher Scientific Inc.
- Waters Corporation
JHS
The global protein engineering market size reached US$ 3.3 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 7.8 Billion by 2032, exhibiting a growth rate (CAGR) of 9.9% during 2024-2032.
Protein engineering refers to the process of developing or changing a protein sequence to achieve the desired result. It involves the synthesis of new proteins or amendments in the existing structure or sequence and employs recombinant deoxyribonucleic acid (DNA) technology to alter amino acid sequences for novel and enhanced functions. It is widely utilized for the production of enzymes or proteins in large quantities for use in industrial settings. In recent years, researchers have successfully engineered a wide range of proteins tailored to medicine, research, industry, health, and biotechnology applications, which is escalating their demand across the globe.
Protein Engineering Market Trends:
The rising investments in synthetic biology and the improving focus toward protein-based drug development represent the primary factors driving the market growth. Additionally, there has been a significant shift toward protein therapeutics from non-protein drugs due to their associated positive clinical outcomes. This, in confluence with the widespread prevalence of protein-deficient diseases, is increasing the demand for protein engineering. Furthermore, several favorable initiatives undertaken by the government of various countries, such as increased funding for research and development (R&D) activities in the field of protein engineering, are propelling the market growth. Besides this, the advent of recombinant monoclonal antibodies (mAbs) and the increasing usage of monoclonal antibodies to treat various diseases, such as cancer and autoimmune diseases, are accelerating product adoption rates. Moreover, the ongoing research for applications of protein engineering in the agrochemical industry to generate enzymes with enhanced function to increase the crop yield or facilitate biofuel production is catalyzing the market growth. Other factors, including the escalating demand for personalized medicines, growing need for biosimilars and biologics, improving healthcare infrastructure, technological advancements, and product innovations, are also creating a positive outlook for the market.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global protein engineering market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on product & services, protein type, technology and end user.
Breakup by Product & Services:
Instruments
Reagents
Services and Software
Breakup by Protein Type:
Insulin
Monoclonal Antibodies
Coagulation Factors
Vaccines
Growth Factors
Others
Breakup by Technology:
Irrational Protein Design
Rational Protein Design
Breakup by End User:
Pharmaceutical and Biotechnology Companies
Academic Research Institutes
Contract Research Organizations
Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abzena Ltd., Agilent Technologies Inc., Amgen Inc., Bio-Rad Laboratories Inc., Bruker Corporation, Codexis Inc., Danaher Corporation, Eli Lilly and Company, General Electric Company, Merck KGaA, Novo Nordisk A/S, PerkinElmer Inc., Thermo Fisher Scientific Inc. and Waters Corporation.
Key Questions Answered in This Report
- 1. What was the size of the global protein engineering market in 2023?
- 2. What is the expected growth rate of the global protein engineering market during 2024-2032?
- 3. What are the key factors driving the global protein engineering market?
- 4. What has been the impact of COVID-19 on the global protein engineering market?
- 5. What is the breakup of the global protein engineering market based on the product and services?
- 6. What is the breakup of the global protein engineering market based on the protein type?
- 7. What is the breakup of the global protein engineering market based on the technology?
- 8. What is the breakup of the global protein engineering market based on the end user?
- 9. What are the key regions in the global protein engineering market?
- 10. Who are the key players/companies in the global protein engineering market?
Table of Contents
1 Preface
2 Scope and Methodology
- 2.1 Objectives of the Study
- 2.2 Stakeholders
- 2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
- 2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
- 2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
- 4.1 Overview
- 4.2 Key Industry Trends
5 Global Protein Engineering Market
- 5.1 Market Overview
- 5.2 Market Performance
- 5.3 Impact of COVID-19
- 5.4 Market Forecast
6 Market Breakup by Product & Services
- 6.1 Instruments
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
- 6.2 Reagents
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
- 6.3 Services and Software
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
7 Market Breakup by Protein Type
- 7.1 Insulin
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
- 7.2 Monoclonal Antibodies
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
- 7.3 Coagulation Factors
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
- 7.4 Vaccines
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
- 7.5 Growth Factors
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
- 7.6 Others
- 7.6.1 Market Trends
- 7.6.2 Market Forecast
8 Market Breakup by Technology
- 8.1 Irrational Protein Design
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
- 8.2 Rational Protein Design
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
9 Market Breakup by End User
- 9.1 Pharmaceutical and Biotechnology Companies
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
- 9.2 Academic Research Institutes
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
- 9.3 Contract Research Organizations
- 9.3.1 Market Trends
- 9.3.2 Market Forecast
10 Market Breakup by Region
- 10.1 North America
- 10.1.1 United States
- 10.1.1.1 Market Trends
- 10.1.1.2 Market Forecast
- 10.1.2 Canada
- 10.1.2.1 Market Trends
- 10.1.2.2 Market Forecast
- 10.2 Asia-Pacific
- 10.2.1 China
- 10.2.1.1 Market Trends
- 10.2.1.2 Market Forecast
- 10.2.2 Japan
- 10.2.2.1 Market Trends
- 10.2.2.2 Market Forecast
- 10.2.3 India
- 10.2.3.1 Market Trends
- 10.2.3.2 Market Forecast
- 10.2.4 South Korea
- 10.2.4.1 Market Trends
- 10.2.4.2 Market Forecast
- 10.2.5 Australia
- 10.2.5.1 Market Trends
- 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
- 10.2.6.1 Market Trends
- 10.2.6.2 Market Forecast
- 10.2.7 Others
- 10.2.7.1 Market Trends
- 10.2.7.2 Market Forecast
- 10.3 Europe
- 10.3.1 Germany
- 10.3.1.1 Market Trends
- 10.3.1.2 Market Forecast
- 10.3.2 France
- 10.3.2.1 Market Trends
- 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
- 10.3.3.1 Market Trends
- 10.3.3.2 Market Forecast
- 10.3.4 Italy
- 10.3.4.1 Market Trends
- 10.3.4.2 Market Forecast
- 10.3.5 Spain
- 10.3.5.1 Market Trends
- 10.3.5.2 Market Forecast
- 10.3.6 Russia
- 10.3.6.1 Market Trends
- 10.3.6.2 Market Forecast
- 10.3.7 Others
- 10.3.7.1 Market Trends
- 10.3.7.2 Market Forecast
- 10.4 Latin America
- 10.4.1 Brazil
- 10.4.1.1 Market Trends
- 10.4.1.2 Market Forecast
- 10.4.2 Mexico
- 10.4.2.1 Market Trends
- 10.4.2.2 Market Forecast
- 10.4.3 Others
- 10.4.3.1 Market Trends
- 10.4.3.2 Market Forecast
- 10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast
11 SWOT Analysis
- 11.1 Overview
- 11.2 Strengths
- 11.3 Weaknesses
- 11.4 Opportunities
- 11.5 Threats
12 Value Chain Analysis
13 Porters Five Forces Analysis
- 13.1 Overview
- 13.2 Bargaining Power of Buyers
- 13.3 Bargaining Power of Suppliers
- 13.4 Degree of Competition
- 13.5 Threat of New Entrants
- 13.6 Threat of Substitutes
14 Price Analysis
15 Competitive Landscape
- 15.1 Market Structure
- 15.2 Key Players
- 15.3 Profiles of Key Players
- 15.3.1 Abzena Ltd.
- 15.3.1.1 Company Overview
- 15.3.1.2 Product Portfolio
- 15.3.2 Agilent Technologies Inc.
- 15.3.2.1 Company Overview
- 15.3.2.2 Product Portfolio
- 15.3.2.3 Financials
- 15.3.2.4 SWOT Analysis
- 15.3.3 Amgen Inc.
- 15.3.3.1 Company Overview
- 15.3.3.2 Product Portfolio
- 15.3.3.3 Financials
- 15.3.3.4 SWOT Analysis
- 15.3.4 Bio-Rad Laboratories Inc.
- 15.3.4.1 Company Overview
- 15.3.4.2 Product Portfolio
- 15.3.4.3 Financials
- 15.3.4.4 SWOT Analysis
- 15.3.5 Bruker Corporation
- 15.3.5.1 Company Overview
- 15.3.5.2 Product Portfolio
- 15.3.5.3 Financials
- 15.3.5.4 SWOT Analysis
- 15.3.6 Codexis Inc.
- 15.3.6.1 Company Overview
- 15.3.6.2 Product Portfolio
- 15.3.6.3 Financials
- 15.3.6.4 SWOT Analysis
- 15.3.7 Danaher Corporation
- 15.3.7.1 Company Overview
- 15.3.7.2 Product Portfolio
- 15.3.7.3 Financials
- 15.3.7.4 SWOT Analysis
- 15.3.8 Eli Lilly and Company
- 15.3.8.1 Company Overview
- 15.3.8.2 Product Portfolio
- 15.3.8.3 Financials
- 15.3.8.4 SWOT Analysis
- 15.3.9 General Electric Company
- 15.3.9.1 Company Overview
- 15.3.9.2 Product Portfolio
- 15.3.9.3 Financials
- 15.3.9.4 SWOT Analysis
- 15.3.10 Merck KGaA
- 15.3.10.1 Company Overview
- 15.3.10.2 Product Portfolio
- 15.3.10.3 Financials
- 15.3.10.4 SWOT Analysis
- 15.3.11 Novo Nordisk A/S
- 15.3.11.1 Company Overview
- 15.3.11.2 Product Portfolio
- 15.3.11.3 Financials
- 15.3.11.4 SWOT Analysis
- 15.3.12 PerkinElmer Inc.
- 15.3.12.1 Company Overview
- 15.3.12.2 Product Portfolio
- 15.3.12.3 Financials
- 15.3.12.4 SWOT Analysis
- 15.3.13 Thermo Fisher Scientific Inc.
- 15.3.13.1 Company Overview
- 15.3.13.2 Product Portfolio
- 15.3.13.3 Financials
- 15.3.13.4 SWOT Analysis
- 15.3.14 Waters Corporation
- 15.3.14.1 Company Overview
- 15.3.14.2 Product Portfolio
- 15.3.14.3 Financials
- 15.3.14.4 SWOT Analysis
